• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Nephrology

Pembrolizumab after nephrectomy improves survival in renal-cell carcinoma patients

byBoaz WongandHarsh Shah
October 4, 2021
in Nephrology, Oncology, Surgery
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Patients receiving adjuvant pembrolizumab after nephrectomy for renal-cell carcinoma showed significantly improved disease-free survival compared to patients receiving placebo treatment.

2. Patients treated with pembrolizumab were shown to have a higher percentage of immune-mediated grade 3 or 4 events compared to patients treated with the placebo.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Patients with locoregional clear-cell renal-cell carcinoma who undergo nephrectomy remain at risk for recurrence after surgery; however, no standard adjuvant treatments are available. Pembrolizumab, an anti-programmed death 1 (PD-1) antibody, is immunotherapy shown to effectively treat advanced renal-cell carcinoma. In this randomized control trial, patients who underwent nephrectomy for renal cell carcinoma and were considered high-risk for recurrence either received 17 cycles of adjuvant pembrolizumab or placebo treatment. The primary measured endpoint was disease-free survival, which was measured from time to first local or distant recurrence, or death of any cause. The study found significantly improved disease-free and overall survival in the group receiving pembrolizumab compared to the placebo. While a higher proportion of patients receiving pembrolizumab experienced severe adverse events, the treatment regimen itself was not associated with any deaths. Together, this phase 3 trial clearly supports the use of pembrolizumab as an adjuvant therapy to nephrectomy in renal-cell carcinoma. The largest limitation to this study was the short follow-up time; therefore, longer intervals are needed to fully assess the effect of adjuvant pembrolizumab on overall survival.

Click to read the study in NEJM

Relevant Reading: Recurrence in Localized Renal Cell Carcinoma: a Systematic Review of Contemporary Data

RELATED REPORTS

Ivonescimab improves survival in advanced non-small cell lung cancer

Transarterial chemoembolization with pembrolizumab and levatinib improves survival in unresectable hepatocellular carcinoma

Bristol Myers Squibb: Opdivo-Qvantig is the first FDA approved subcutaneous version of cancer immunotherapy targeting PD-1

In-Depth [randomized controlled trial]: This open-label, multicenter, phase 3 randomized control trial enrolled 496 patients from 213 sites in 21 countries. Patients who were at least 18 years of age, previously underwent nephrectomy for locoregional clear-cell renal-cell carcinoma, and were considered high-risk for recurrence were included in the study. Patients who received any previous systemic therapy or had not undergone gone surgery were excluded from the study. Participants were randomized in a 1:1 ratio to receive 17 cycles of 200mg adjuvant pembrolizumab or placebo saline treatment, respectively. The primary assessed endpoint was disease-free survival defined as the time of treatment to first local or distant recurrence, or death for any reason. At 24 months, patients receiving pembrolizumab showed significantly improved disease-free survival compared to their placebo counterparts (hazard ratio for recurrence or death [HR], 0.68; 95% confidence interval [CI], 0.53 to 0.87, P=0.002). Pembrolizumab was able to improve the percentage of patients who remained recurrence-free and alive at 24 months (77.3%) compared to the placebo group (68.1%). Patients receiving pembrolizumab also experienced improved overall survival at 96.6% after 24 months compared to 93.5% in the placebo (HR, 0.54; 95%CI, 0.30 to 0.96). No deaths were directly attributable to the treatment regimen. Finally, a greater proportion of immune-mediated adverse events were shown in the pembrolizumab group (34.6%) compared to the placebo group (5.8%). Together, at its first interim analysis, this study supports the use of adjuvant pembrolizumab after partial or complete nephrectomy in patients with clear-cell renal-cell carcinoma.

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Nephrectomyoverall survivalPembrolizumabrenal-cell carcinoma
Previous Post

Ivosidenib improves overall survival in IDH1-mutant advanced cholangiocarcinoma as compared to placebo

Next Post

Atogepant effective in reducing migraine and headache days

RelatedReports

Lessons from real-world implementation of lung cancer screening
Chronic Disease

Ivonescimab improves survival in advanced non-small cell lung cancer

April 30, 2025
Prognostic indicators for transarterial chemoembolization in patients with hepatocellular carcinoma with extrahepatic spread identified
Chronic Disease

Transarterial chemoembolization with pembrolizumab and levatinib improves survival in unresectable hepatocellular carcinoma

March 5, 2025
Radiographic surrogates may predict tumor-specific survival in renal carcinoma
Pharma

Bristol Myers Squibb: Opdivo-Qvantig is the first FDA approved subcutaneous version of cancer immunotherapy targeting PD-1

February 17, 2025
Increased frailty associated with childhood cancer survivorship
Chronic Disease

Pembrolizumab with radiotherapy and surgery improves survival in high-risk soft tissue sarcoma

December 19, 2024
Next Post
Patients report persistent quality-of-life impairments following ruptured brain aneurysms

Atogepant effective in reducing migraine and headache days

New York reports 15 child cases of rare disease linked to COVID-19

No differences in pain between suture and staple C-Section closure

Prolongation of passive second stage of labour not associated with increased risk of hysterotomy extension during cesarean

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Dapagliflozin may improve outcomes in patients with metabolic dysfunction-associated steatohepatitis
  • Early induction of labour reduces shoulder dystocia rates in large for gestational age fetuses
  • Sacituzumab tirumotecan may have a role in the treatment of metastatic non-small cell lung cancer
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.